XenoPort Inc. (Nasdaq: XNPT) announced today that it will present the following posters at the 65th Annual Meeting of the American Academy of Neurology in San Diego California:
AP (arbaclofen placarbil)Spasticity
XP23829Preclinical and Phase 1 Studies
XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended Release Tabletsis our first approved product in the United States. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30 2013 following which XenoPort will be responsible for the further development manufacturing and commercialization of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity Parkinson's disease relapsing-remitting multiple sclerosis and/or psoriasis.
To learn more about XenoPort please visit the web site at www.XenoPort.com.
Horizant Regnite and XENOPORT are registered trademarks of XenoPort Inc.
Source code: XNPT2CBusiness Wire
Last updated on: 18/03/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.